KT-HEALTHC RMF invests in the master fund Janus Henderson Global Life Sciences Fund (Ireland). Actual total expense ratio (TER) 1.97% a year. Pays no dividends. Data as of 16 Nov 2026.
KTAM World Healthcare RMF
Shows where this fund stands in its group. Not investment advice · Data as of 16 Nov 2026
KT-HEALTHC RMF invests through the master fund Janus Henderson Global Life Sciences Fund 98.97%
This fund and the master fund each charge their own fees. See the fees section of this page for the actual fees
Data as of 31 Oct 2026 · Top 6 shown, the rest grouped as Other · per Janus Henderson fact sheet
Over the past year it was above its group median; over 5 years it returned +3.78% per year (Top 25% of the group)
| Return | SD | MDD | Return/SD | |
|---|---|---|---|---|
| YTD | +13.81% | −9.37% | ||
| 1D | −1.16% | −1.16% | ||
| 1W | −1.45% | −1.45% | ||
| 2W | +1.99% | −3.15% | ||
| 1M | +6.71% | −3.15% | ||
| 3M | +4.32% | −9.27% | ||
| 6M | +17.94% | −9.27% | ||
| 1Y | +16.19% | 17.92% | −9.37% | +0.90 |
| 3Y | +41.56%+12.28%/yr | 17.21% | −23.26% | +0.71 |
| 5Y | +20.36%+3.78%/yr | 17.82% | −23.26% | +0.21 |
| 7Y | +62.09%+7.14%/yr | 19.71% | −26.77% | +0.36 |
| 10Y | +106.86%+7.54%/yr | 18.30% | −26.77% | +0.41 |
| MAX | +82.40%+5.64%/yr | 18.50% | −26.77% | +0.30 |
| Return | MDD | SD | Return/SD | |
|---|---|---|---|---|
| YTD | +13.81% | −9.37% | ||
| 1D | −1.16% | −1.16% | ||
| 1W | −1.45% | −1.45% |
Past performance is not a guarantee of future results
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Full year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +0.1 | +1.5 | −5.5 | +1.2 | +1.8 | +8.4 | −0.7 | +3.2 |
Largest drawdown in the selected period −26.77% Previous peak 21 Feb 2020 (NAV 12.3703) → Trough 23 Mar 2020 (NAV 9.0588) · Back to the previous peak on 19 Jun 2020, after 2 months
Currently −1.45% from the peak NAV of 18.5052 (9 Nov 2026)
Over 10 years, KT-HEALTHC RMF returned 0.41 per unit of SD, ranking 8 of 21 funds · The highest is FP HCARE-A (0.48)
กองทุนเน้นลงทุนในหน่วยลงทุนของกองทุน Janus Henderson Global Life Sciences Fund (Master Fund) เพียงกองเดียว โดยเฉลี่ยในรอบปีบัญชี ไม่น้อยกว่าร้อยละ 80 ของมูลค่าทรัพย์สินสุทธิของกองทุนรวม หรือตามอัตราส่วนที่สำนักงานคณะกรรมการ ก.ล.ต. จะประกาศกำหนด Its largest holdings are หน่วยลงทุน Janus Global Life Sciences Fund 99.59% (fact sheet 30 Sep 2026)
Risk level 7 of 8 (High risk). Since 30 Nov 2015, its NAV has fallen as much as −26.77% from its peak.
Actual total expense ratio (TER) 1.97% a year, against a ceiling of 5.35%. Management fee 1.34%. Front-end fee 0.00%. Back-end fee 0.00%. (Fact sheet 31 Aug 2026)
No. Gains or losses accumulate in the NAV, and investors receive their return when they redeem units
Warning Past performance is not a guarantee of future results · Investing involves risk. Investors should understand the product's features, return conditions and risks before making an investment decision · This fund invests abroad, so investors may lose or gain from exchange rate movements
Diabetes and weight-loss drugs
An American medicines and medical devices company, with products such as cancer drugs and surgical instruments
Hospitals, medicines and medical equipment
Hospitals, medicines and medical equipment
Hospitals, medicines and medical equipment
Based on the master fund's share of this fund's value (98.97% as of 31 Aug 2026) × each stock's weight in the master fund · stocks as of 31 Oct 2026 · fact sheet from Janus Henderson · Illustrations are for explanation only, not individual stock recommendations
| 2W | +1.99% | −3.15% |
| 1M | +6.71% | −3.15% |
| 3M | +4.32% | −9.27% |
| 6M | +17.94% | −9.27% |
| 1Y | +16.19% | −9.37% | 17.92% | +0.90 |
| 3Y | +41.56%+12.28%/yr | −23.26% | 17.21% | +0.71 |
| 5Y | +20.36%+3.78%/yr | −23.26% | 17.82% | +0.21 |
| 7Y | +62.09%+7.14%/yr | −26.77% | 19.71% | +0.36 |
| 10Y | +106.86%+7.54%/yr | −26.77% | 18.30% | +0.41 |
| MAX | +82.40%+5.64%/yr | −26.77% | 18.50% | +0.30 |
No. 1 is SCBGENOME(E) +49.91%
No. 1 is TBIOTECH +23.13% per year
No. 1 is TBIOTECH +7.82% per year
No. 1 is FP HCARE-A +10.07% per year
No. 1 is SCBRMGHC +8.27% per year
Each bar is one fund in the AIMC Health Care group, sorted from highest to lowest return · Every share class is counted, and only funds with a full track record for the period are included · Calculated from NAV as of 16 Nov 2026
| −4.1 |
| +6.6 |
| +1.4 |
| · |
| +13.8* |
| 2025 | +5.4 | −0.0 | −4.1 | −2.5 | −6.8 | +1.5 | −0.9 | +5.4 | +2.2 | +8.3 | +8.7 | −1.4 | +15.5 |
|---|
| 2024 | +2.6 | +3.8 | +1.5 | −4.8 | +2.9 | +2.7 | +1.7 | +3.4 | −3.4 | −2.6 | −1.1 | −8.1 | −2.1 |
|---|
| 2023 | −0.6 | −4.1 | +1.6 | +3.6 | −2.7 | +2.7 | −0.1 | −1.6 | −3.5 | −7.1 | +6.4 | +6.6 | +0.0 |
|---|
| 2022 | −12.7 | +4.1 | +3.5 | −6.4 | −1.2 | −0.3 | +4.9 | −3.8 | −2.8 | +8.1 | +3.7 | −1.7 | −6.4 |
|---|
| Average | −0.4 | +0.1 | −0.9 | +0.9 | +0.2 | +3.0 | +1.6 | +0.9 | −1.5 | −0.1 | +3.2 | −0.1 | +5.5 |
|---|
Minimum first purchase 500 THB, subsequent purchases 500 THB. Buy orders accepted until 15:30, sell orders until 15:30, and redemption proceeds are paid T+4
KT-HEALTHC RMF is a retirement mutual fund (RMF). You can buy up to 30% of your assessable income, capped at 500,000 THB a year together with other retirement funds. You must hold it for at least 5 years and can sell only once you turn 55. Check the latest conditions with the Revenue Department before investing
Hedged at the manager's discretion. As of 30 Sep 2026, 70.83% of the value of its foreign investments was hedged